Retraction Note: Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus.

导出 LinkOut

翻译打印收藏纠错

作者： Jiangnan,Zhao ^[1] ; Meiying,Zhu ^[1] ; Hao,Jiang ^[2] ; Simen,Shen ^[3] ; Xin,Su ^[1] ; Yi,Shi ^[4]

作者单位： Department of Respiratory and Critical Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China. ^[1] Department of Emergency Medicine, the Second Affiliated Hospital, Southeast University, Nanjing, 210002, China. ^[2] Department of Respiratory Medicine, the First People's Hospital of Nantong, Nantong, 226000, China. ^[3] Department of Respiratory and Critical Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China. yishi201607@163.com. ^[4]

DOI 10.1038/s41598-023-34694-8

PMID 37165053

发布时间 2023-05-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Scientific reports

2023年13卷1期

7592页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Retraction Note: Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus.

Scientific reports

相似文献

Scientific reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Retraction Note: Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus.

Scientific reports

相似文献

Scientific reports

相关期刊

检索历史清除